Breaking News

An immaculate infection and a brain cancer breakthrough

September 13, 2024
lev_facher_100
Addiction Reporter

Good morning! It's Lev Facher, STAT's addiction reporter, subbing for Theresa. Before we get into the news, a quick note: Yesterday's newsletter included a bad link for Jason Mast's story on drug development for rare childhood diseases. Make sure to read it here!

bird flu

Immaculate infection: Missouri bird flu case remains a mystery

Disease investigators still don't know how a Missouri resident with no known exposures to sick animals or poultry became infected with the H5 bird flu virus. The good news, however, is that the CDC's ongoing investigation has turned up no evidence of further transmission, according to Nirav Shah, the agency's principal deputy director. 

"Here's the bottom line: Our influenza surveillance system is designed to find needles in haystacks," Shah said. "Here in this case, we found such a needle, but we don't know how it got there." 

Federal officials have identified bird flu cases in 203 cattle flocks since late March. The U.S. has recorded 14 cases of known human infection in that span. Read more from STAT's Helen Branswell here.


public health

CDC warns of ever-worsening obesity prevalence 

In 2018, the CDC warned that in seven states, the adult obesity rate was 35% or higher. Six years later, a total of 23 states, plus Guam and Puerto Rico, have obesity rates of 35% or higher, and 20% of adults in all 50 states are living with obesity, according to numbers released Thursday. 

The CDC's data showed geographical differences, with higher obesity rates in the Midwest and the South and lower rates in California, New York, and much of the Northeast. Pennsylvania and Kentucky did not report sufficient data, and among the jurisdictions that did, only Colorado and the District of Columbia reported obesity rates of under 25%. It also showed significant racial disparities: Asian adults did not have an obesity prevalence of over 35% in any state, while Hispanic and Black adults hit the 35% threshold in 34 and 38 states, respectively. 

One potential silver lining: The announcement comes amid the proliferation of the popular class of GLP-1 drugs used to treat diabetes and obesity under brand names like Ozempic and Wegovy, which the CDC specifically cited in its press release.


 first opinion

A cardiologist warns against compounded semaglutide

GLP-1 drugs like Ozempic and Wegovy may represent a breakthrough when it comes to treating obesity and weight-related conditions like diabetes and hypertension. But the medications are expensive and hard to find — leading many people seeking their active ingredient, semaglutide, to buy it from compounding pharmacies, which mix and combine different ingredients to effectively create custom medications, selling it for pennies on the dollar. 

One cardiologist is now arguing that the benefits of cheaper and more accessible semaglutide don't outweigh the risks. In recent years, the FDA has received numerous reports of compounded semaglutide being adulterated with toxins or impurities. Even when manufactured properly, it can be hard to use — perhaps explaining why poison control centers have received thousands of reports of overdoses stemming from compounded semaglutide.

In a First Opinion for STAT, cardiologist Vishal Khetpal calls for more regulation of compounded semaglutide and argues for pricing measures that could make the drug in its typical form more widely available to patients, regardless of income level. Read more here. 



health

A brain cancer breakthrough decades in the making

240910_STATNEWS-BRAINTUMOR_JOSEALVARADOJR_0262-1

José A. Alvarado Jr. for STAT

A new medication helped people with brain tumors stave off disease progression for over a year compared to trial participants taking a placebo — a thrilling breakthrough for researchers, patients, and drug developers who've spent decades searching for better treatments. The new drug, Voranigo, received FDA approval last month and could be the harbinger of a new era for pharmaceutical industry interest in treating certain brain cancers. 

There are a few catches, of course: Studies suggest the potential for harm to the liver, and the drug is approved only for patients with specific types of brain tumors and with specific mutations of two related genes. (One such patient is Rachel Guberman, pictured above.) Even for those who do qualify, the drug's current list price is nearly $480,000 per year. 

Still, the drug is generating significant buzz. "This is the most exciting thing I've ever encountered," said Katherine Peters, a Duke University neuro-oncologist and one of the clinical trial investigators. Read more from STAT's Andrew Joseph.


health tech

Behavioral health groups ask Congress to act on telehealth prescribing rights 

A coalition of mental health and addiction treatment groups is begging Capitol Hill for a two-year extension of the emergency telehealth prescribing rights they gained during the Covid-19 pandemic. 

In a letter delivered to Congressional leadership and the Biden administration this week, the group asked lawmakers to effectively short-circuit a regulation currently being considered by the Drug Enforcement Administration. The rule would re-impose some in-person requirements on patients seeking medications like stimulants for ADHD or buprenorphine, a common and highly effective medication used to treat opioid addiction. It was first proposed in early 2023 and is likely to be finalized before the end of President Biden's term. 

The groups include the National Council for Mental Wellbeing, American Psychiatric Association, and American Pharmacists Association, as well as behavioral health startups that have blossomed during the telehealth era, such as Boulder Care, Bicycle Health, and Pelago.


addiction

Key Democrats look to crack down on problem gambling

Sen. Richard Blumenthal (D-Conn.) and Rep. Paul Tonko (D-N.Y.) introduced a new bill Thursday meant to guard against the rise of sports books that can be accessed via cell phone, and gambling-related harms more broadly.

The SAFE Bet Act, as the legislation is known, would ban online sports book advertising during live sporting events and prohibit offers meant to induce gambling, including boosted odds and free "bonus" bets. It would also place limits on user deposits within a 24-hour period, prohibit the use of AI to offer individualized promotions to consumers, and require sports books to conduct "affordability checks" on their customers before accepting large wagers. 

As states rush to legalize online sports betting, many lawmakers and public health officials have fretted about opening the floodgates to yet another addiction-related health crisis. As I reported in June, gambling behavior, especially when coupled with substance use, is a known risk factor for depression and suicide — and increasingly, addiction professionals feel they have no choice but to fold gambling-related care into their broader treatment portfolio.


More around STAT
Check out more exclusive coverage with a STAT+ subscription
Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

What we're reading

  • Thanks to a new FDA-approved treatment, my hair is growing — but so is the feeling that I've lost something, The Cut

  •  Insurers went all-in on Medicare Advantage. Now, some are scaling back, STAT

  •  After Shark Tank, Mark Cuban just wants to break shit — especially the prescription drug industry, Wired

  •  Gaza is vaccinating against polio. Is the virus a threat to the U.S.?, The Washington Post
  • Why these health tech leaders are making a risky bet, openly backing Trump or Harris, STAT
  •  

Thanks for reading! More on Monday — Lev


Enjoying Morning Rounds? Tell us about your experience
Continue reading the latest health & science news with the STAT app
Download on the App Store or get it on Google Play
STAT
STAT, 1 Exchange Place, Boston, MA
©2024, All Rights Reserved.

No comments